Since synaptic dysfunction is an important phenotypic manifestation of AD14, 20, 22, 38, it can be speculated that there may be a molecular link to AD pathogenesis that will allow dynamin 1 and PSD-95 to be useful as biomarkers for evaluating prospective treatments for AD. This evidence concerns the gene DNM1 and Alzheimer disease.